Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 41: 1504-1508, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breimer, L. H.
Right arrow Articles by Shaper, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breimer, L. H.
Right arrow Articles by Shaper, A. G.

Clinical Chemistry, Vol 41, 1504-1508, Copyright © 1995 by American Association for Clinical Chemistry

Serum bilirubin and risk of ischemic heart disease in middle-aged British men

LH Breimer, G Wannamethee, S Ebrahim and AG Shaper
Department of Clinical Pathology, Royal Free Hospital School of Medicine, London, UK.

The possibility that low concentrations of serum bilirubin may be associated with increased risk of ischemic heart disease has been examined in a prospective study of 7685 middle-aged British men. During 11.5 years there were 737 major ischemic heart disease (IHD) events. A U-shaped relationship was observed between serum bilirubin and risk of IHD. Low bilirubin was associated with several cardiovascular risk factors, in particular smoking, low concentrations of high-density lipoprotein cholesterol, low forced expiratory volume in 1 s, and low serum albumin. The U-shaped relationship persisted even after adjusting for several risk factors. Compared with men in the lowest fifth of the distribution (bilirubin < 7 mumol/L), those in the middle range (8-9 mumol/L) showed a 30% reduction in relative risk [RR = 0.68 (95% confidence intervals 0.51-0.89)] in IHD, whereas men in the top fifth (> 12 mumol/L) showed similar risk to the lowest fifth [RR = 0.99 (95% confidence intervals 0.73-1.34)], which persisted after exclusion of men with bilirubin > 17 mumol/L. The significance of this U-shaped relationship is unclear, but it could be interpreted as support for the role of endogenous antioxidants in the etiology of IHD.


The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg
Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study
Clin. Chem., May 1, 2008; 54(5): 851 - 857.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. S. Perlstein, R. L. Pande, J. A. Beckman, and M. A. Creager
Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 166 - 172.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. M. van der Bol, R. H.J. Mathijssen, W. J. Loos, L. E. Friberg, R. H.N. van Schaik, M. J.A. de Jonge, A. S.Th. Planting, J. Verweij, A. Sparreboom, and F. A. de Jong
Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia
J. Clin. Oncol., July 1, 2007; 25(19): 2719 - 2726.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. W. Ryter, D. Morse, and A. M. K. Choi
Carbon Monoxide and Bilirubin: Potential Therapies for Pulmonary/Vascular Injury and Disease
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 175 - 182.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-P. Lin, C. J. O'Donnell, J. P. Schwaiger, L. A. Cupples, A. Lingenhel, S. C. Hunt, S. Yang, and F. Kronenberg
Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study
Circulation, October 3, 2006; 114(14): 1476 - 1481.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. W. Ryter, J. Alam, and A. M. K. Choi
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
Physiol Rev, April 1, 2006; 86(2): 583 - 650.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Gullu, D. Erdogan, D. Tok, S. Topcu, M. Caliskan, T. Ulus, and H. Muderrisoglu
High Serum Bilirubin Concentrations Preserve Coronary Flow Reserve and Coronary Microvascular Functions
Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2289 - 2294.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Morita
Heme Oxygenase and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1786 - 1795.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Keshavan, T. L. Deem, S. J. Schwemberger, G. F. Babcock, J. M. Cook-Mills, and S. D. Zucker
Unconjugated Bilirubin Inhibits VCAM-1-Mediated Transendothelial Leukocyte Migration
J. Immunol., March 15, 2005; 174(6): 3709 - 3718.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
T. W. Sedlak and S. H. Snyder
Bilirubin Benefits: Cellular Protection by a Biliverdin Reductase Antioxidant Cycle
Pediatrics, June 1, 2004; 113(6): 1776 - 1782.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
H. A. Schwertner
Bilirubin Concentration, UGT1A1*28 Polymorphism, and Coronary Artery Disease
Clin. Chem., July 1, 2003; 49(7): 1039 - 1040.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
P. J. Bosma, I. M. van der Meer, C. T. Bakker, A. Hofman, M. Paul-Abrahamse, and J. C. Witteman
UGT1A1*28 Allele and Coronary Heart Disease: The Rotterdam Study
Clin. Chem., July 1, 2003; 49(7): 1180 - 1181.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
G. Endler, A. Hamwi, R. Sunder-Plassmann, M. Exner, T. Vukovich, C. Mannhalter, J. Wojta, K. Huber, and O. Wagner
Is Low Serum Bilirubin an Independent Risk Factor for Coronary Artery Disease in Men but Not in Women?
Clin. Chem., July 1, 2003; 49(7): 1201 - 1204.
[Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
L. Novotny and L. Vitek
Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies
Experimental Biology and Medicine, May 1, 2003; 228(5): 568 - 571.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
W. Durante
Carbon monoxide and bile pigments: surprising mediators of vascular function
Vascular Medicine, August 1, 2002; 7(3): 195 - 202.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
M. Mayer
Association of Serum Bilirubin Concentration with Risk of Coronary Artery Disease
Clin. Chem., November 1, 2000; 46(11): 1723 - 1727.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. E. Clark, R. Foresti, P. Sarathchandra, H. Kaur, C. J. Green, and R. Motterlini
Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction
Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H643 - H651.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. C. Hunt, L. L. Wu, P. N. Hopkins, and R. R. Williams
Evidence for a Major Gene Elevating Serum Bilirubin Concentration in Utah Pedigrees
Arterioscler. Thromb. Vasc. Biol., August 1, 1996; 16(8): 912 - 917.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.